Over-expression of p53 and c-erbB-2 oncoproteins in laryngeal carcinoma

Kazkayasi, Mustafa; Hücümeno&gcaron;lu, Sema; Siriner, Gerç I.; Hücümeno&gcaron;lu, Mahmut
September 2001
European Archives of Oto-Rhino-Laryngology;Sep2001, Vol. 258 Issue 7, p329
Academic Journal
An immunohistochemical analysis of over-expression of p53 and c-erbB-2 proteins was performed on 27 biopsies of laryngeal carcinoma. The aim of this study was to investigate whether there is a correlation between over-expression of these proteins and the clinicopathological features of the tumor and to reveal any possible prognostic value. Paraffin sections of laryngeal carcinoma were studied using immunohistochemical staining with mouse and rabbit monoclonal antibodies, respectively, for p53 and c-erbB-2 proteins. The positive controls were paraffin-embedded specimens from ten breast carcinomas previously shown to express these proteins. Ten benign laryngeal nodules were immunohistochemically stained as negative controls. Samples from 74% of 27 patients with laryngeal carcinomas demonstrated positive nuclear and cytoplasmic (or membranous) staining for p53 protein and 48% were positive for c-erbB-2 protein. In the present study, while there was a slight difference in the frequency of p53 over-expression among stage I–II and stage III–IV tumors, there was no difference in the frequency of p53 over-expression among primary and recurrent tumors. There was no statistically significant correlation between over-expression of the p53 and c-erbB-2 proteins and the age of the patients, tumor site, tumor grade, clinical stage, histopathological grading of the tumor, alcohol consumption, and clinical outcome. There was a statistically significant correlation between immunostaining of p53 and c-erbB-2 proteins (P = 0.037). While it was found that over-expression of p53 was significantly associated with the presence of lymph node metastasis (P = 0.006), there was no association between the expression of c-erbB-2 and lymph node status. The data demonstrated increased expression of p53 and c-erbB-2 proteins, presumed to be mutant, in laryngeal carcinomas. Hence, we conclude that p53 and c-erbB-2 over-expression as detected by immunohistochemical staining in larynx carcinomas is not predictive of poor survival or disease-free survival.


Related Articles

  • P53 Codon 72 and HER2 Codon 655 Polymorphisms in Turkish Breast Cancer Patients. Kara, Nurten; Karakus, Nevin; Ulusoy, Ali Naki; Ozaslan, Cihangir; Gungor, Bulent; Bagci, Hasan // DNA & Cell Biology;Jul2010, Vol. 29 Issue 7, p387 

    The polymorphisms in codon 72 of the tumor suppressor protein p53 ( P53) gene and codon 655 of the human epidermal growth factor receptor 2 ( HER2) gene have been suggested to play roles in most cancers. The purpose of this study was to investigate the association between common variants of...

  • The ins and outs of p53. Vousden, Karen H.; Woude, George F. Vande // Nature Cell Biology;Oct2000, Vol. 2 Issue 10, pE178 

    Moving proteins between cellular locations is proving to be a tightly regulated process, and provides an important mechanism for controlling protein function. The tumour-suppressor protein p53 has been shown to use microtubules to aid nuclear localization, a finding that raises interesting...

  • P53 Tumor Suppression and Metabolic, Antioxidant Effects. Breindl, Anette // BioWorld Today;6/11/2012, Vol. 23 Issue 112, Special section p1 

    The article deals with a study published in the June 8, 2012 issue of "Cell," which found that the unconventional activities of p53 protein like metabolic regulation and antioxidant function contribute to its ability to suppress early-onset spontaneous tumorigenesis.

  • p53 and p73: seeing double? Soengas, María S; Lowe, Scott W // Nature Genetics;Dec2000, Vol. 26 Issue 4, p391 

    Whereas p73 is closely related to the tumour-suppressor protein p53, its contribution to tumour suppression and the spatial and temporal regulation of its isoforms is unclear. It has now been established that p73 is a transcriptional target of E2F1. Its ability to induce apoptosis in...

  • Versatile functions of p53 protein in multicellular organisms. Chumakov, P. M. // Biochemistry (00062979);Dec2007, Vol. 72 Issue 13, p1399 

    The p53 tumor suppressor plays a pivotal role in multicellular organism by enforcing benefits of the organism over those of an individual cell. The task of p53 is to control the integrity and correctness of all processes in each individual cell and in the organism as a whole. Information about...

  • Dual roles of Drosophila p53 in cell death and cell differentiation. Fan, Y.; Lee, T. V.; Xu, D.; Chen, Z.; Lamblin, A.-F.; Steller, H.; Bergmann, A. // Cell Death & Differentiation;Jun2010, Vol. 17 Issue 6, p912 

    The mammalian p53 family consists of p53, p63 and p73. Whereas p53 accounts for tumor suppression through cell-cycle arrest and apoptosis, the functions of p63 and p73 are more diverse and also include control of cell differentiation. The Drosophila genome contains only one p53 homolog, Dp53....

  • Out of the jaws of death: PRMT5 steers p53. Berger, Shelley L. // Nature Cell Biology;Dec2008, Vol. 10 Issue 12, p1389 

    The tumour suppressor p53 triggers either cell-cycle arrest or apoptosis. Now, arginine methylation joins a panoply of other post-translational modifications that regulate p53. PRMT5 mediates p53 methylation, which disposes the cell to arrest rather than death.

  • Interaction of the HPV E7 proteins with the pCAF acetyltransferase. Avvakumov, Nikita; Torchia, Joe; Mymryk, Joe S // Oncogene;6/19/2003, Vol. 22 Issue 25, p3833 

    Most cervical carcinomas express the E6 and E7 proteins of a high-risk human papillomavirus (HPV). These proteins affect growth control by interfering with the functions of cell regulatory proteins, promoting oncogenic transformation. A key target of E7 is the tumor suppressor protein pRb, which...

  • Mdm2-mediated ubiquitylation: p53 and beyond. Marine, J.-C.; Lozano, G. // Cell Death & Differentiation;Jan2010, Vol. 17 Issue 1, p93 

    The really interesting genes (RING)-finger-containing oncoprotein, Mdm2, is a promising drug target for cancer therapy. A key Mdm2 function is to promote ubiquitylation and proteasomal-dependent degradation of the tumor suppressor protein p53. Recent reports provide novel important insights into...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics